The short version of Prohibited substance fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Uranium–lead radiometric dating involves using uranium-235 or uranium-238 to date a substance's absolute age. This scheme has been refined to the point that the error margin in dates of rocks can be as low as less than two million years in two-and-a-half billion years. An error margin of 2–5% has been achieved on younger Mesozoic rocks. Uranium–lead dating is often performed on the mineral zircon (ZrSiO4), though it can be used on other materials, such as baddeleyite and monazite (see: monazite geochronology). Zircon and baddeleyite incorporate uranium atoms into their crystalline structure as substitutes for zirconium, but strongly reject lead. Zircon has a very high closure temperature, is resistant to mechanical weathering and is very chemically inert. Zircon also forms multiple crystal layers during metamorphic events, which each may record an isotopic age of the event. In situ micro-beam analysis can be achieved via laser ICP-MS or SIMS techniques. One of its great advantages is that any sample provides two clocks, one based on uranium-235's decay to lead-207 with a half-life of about 700 million years, and one based on uranium-238's decay to lead-206 with a half-life of about 4.5 billion years, providing a built-in crosscheck that allows accurate determination of the age of the sample even if some of the lead has been lost. This can be seen in the concordia diagram, where the samples plot along an errorchron (straight line) which intersects the concordia curve at the age of the sample.
=== Gonads and sexual development === In mice, adropin treatment significantly increased sperm count and testicular testosterone by increasing expression of GPR19 and steroidogenic proteins via modulating redox potential. In the mouse ovary, adropin and GPR19 are strongly detected in the granulosa cells of large antral follicles and corpus luteum. An additional study suggests a role for adropin in the acceleration of pubertal development.
=== Post-peptide modifications === The modification required to biosynthesize mature chloroeremomycin include: oxidative cross-linking of aromatic rings, hydroxylation and chlorination of the two Tyr residues, methylation of Leu, and glycosylation at aa4 and aa6. The oxidative crosslinks are catalyzed by enzymes OxyA-C. The glycosylations are catalyzed by enzymes GtfA-C (coded by Orf11-13 respectively). The chlorinations are performed by enzymes encoded by Orf10 and 18.
Sources: en.wikipedia.org
(1933), first African-American basketball player to be selected as All-American Alfred Skrobisch (1933), Olympic fencer Cliff Montgomery (1934), led the Columbia Lions football team to victory in the Rose Bowl John O'Brien (1938), basketball player for the Akron Wingfoots Ben Johnson (1938), sprinter who rivaled Jesse Owens Sid Luckman (1939), NFL Hall of Fame Chicago Bears quarterback Ken Germann (1943), football coach, athletic director of Columbia University, and former Southern Conference commissioner Paul Governali (1943), football player for the Boston Yanks and New York Giants Walt Budko (1948), basketball player for Baltimore Bullets and Philadelphia Warriors Bruce Gehrke (1948), football player for New York Giants Bill Swiacki (1948), player for New York Giants, member of the College Football Hall of Fame Lou Kusserow (1949), football player for Hamilton Tiger-Cats and New York Yanks John Azary (1951), basketball player, recipient of the Haggerty Award Jack Molinas (1953), NBA player for the Fort Wayne Pistons Jack Rohan (1953), head coach of the Columbia Lions men's basketball team 1961–1974, and 1990–1995 George Shaw (1953), Olympic triple jumper Richard Ballantine* (1967), cyclist and cycling advocate; son of Ian Ballantine '38 of Ballantine Books James Margolis (1958), Olympic fencer James Melcher (1961), Olympian fencer, president of Fencers Club and hedge fund manager Robert Contiguglia (1963), soccer player, former president of the United States Soccer Federation Peter Salzberg (1964), head coach of Vermont Catamounts men's basketball 1972–1981 Archie Roberts (1965), former football player for the Miami Dolphins and cardiac surgeon Jim McMillian (1968), NBA player for the Los Angeles Lakers, Buffalo Braves, New York Knicks and Portland Trail Blazers Dave Newmark (1968), NBA player for the Chicago Bulls; also played for Israeli team Hapoel Tel Aviv B.C. Marty Domres (1969), football player for San Diego Chargers and Baltimore Colts Heyward Dotson (1970), basketball player George Starke (1971), offensive lineman for the Washington Redskins Henry Bunis (1975), two-time All-American tennis player, runner-up in 1977 Chilean Open Rick Fagel (1975), professional tennis player Vitas Gerulaitis* (1975), champion tennis player Thomas Losonczy (1975), Olympic fencer, winner of the Congressional Gold Medal Alton Byrd (1979), basketball player Eric Fromm (1980), tennis player John Witkowski (1983), football player for Detroit Lions and Houston Oilers Gene Larkin (1984), member of the Minnesota Twins 1987 and 1991 World Series championship teams Amr Aly (1985), soccer player who won the Hermann Trophy as the top college player of the year 1984; member of the 1984 U.S. Olympic Soccer Team and indoor soccer team Los Angeles Lazers Stephen Trevor (1986), Olympic fencer Kyra Tirana Barry (1987), team leader for U.S. women's national wrestling team Caitlin Bilodeaux (1987), Olympic fencer Howard Endelman (1987), tennis player Phil Williamson (1987), tennis player for Antigua and Barbuda Bob Cottingham (1988), Olympic fencer Jon Normile (1989), Olympic fencer Frank Seminara (1989), Major League Baseball pitcher for the San Diego Padres and the New York Mets Tom Auth (1990), Olympic rower Christine Vardaros (1991), professional cyclist Ann Marsh (1994), Olympic fencer Ríkharður Daðason (1996), Icelandic soccer player Marcellus Wiley (1997), football player for the Buffalo Bills, San Diego Chargers and Dallas Cowboys Dan Kellner (1998), fencer Pellegrino Matarazzo (1999), head coach of VfB Stuttgart Matt Napoleon (1999), Olympic soccer goalkeeper Cristina Teuscher (2000), Olympic gold medalist swimmer Jedediah Dupree (2001), NCAA Champion fencer Veljko Urošević (2003), Serbian Olympic rower Fernando Perez (2004), outfielder for the Tampa Bay Rays Jeremiah Boswell (2005), professional basketball player for BC Sliven, KK Strumica, and KK Torus Delilah DiCrescenzo (2005), long-distance runner, inspiration and subject of the Grammy-nominated song Hey There Delilah Michael Quarshie (2005), Finnish American football player who played for the Oakland Raiders and Frankfurt Galaxy Lisa Nemec (2006), Croatian long-distance runner Miloš Tomić (2006), Serbian Olympic rower Erison Hurtault (2007), Dominican sprinter James Leighman Williams (2007), fencer who won silver in the 2008 Summer Olympics Emily Jacobson (2008), fencer İhsan Emre Vural (2008), Turkish rower for Galatasaray S.K. Sherif Farrag (2009), Egyptian-American Olympic fencer Nicholas la Cava (2009), Olympic rower Jeff Spear (2010), Olympic fencer Daria Schneider (2010), fencer Jeff Adams (2011), Houston Texans offensive tackle Nicole Ross (2011), Olympic fencer Isadora Cerullo (2013), Brazilian-American Olympic rugby player Katie Meili (2013), Olympic swimmer, Pan American Games and 2016 Summer Olympics gold medalist Josh Martin (2013), Kansas City Chiefs linebacker John Gregorek Jr. (2014), middle-distance runner David Najem (2014), American soccer player for New Mexico United and the Afghanistan national football team Nadia Eke (2015), Ghanaian triple jumper, African Championships gold medalist in 2016 Kristine Musademba (2015), figure skater Max Schnur (2015), tennis player playing on the ATP Challenger Tour Nzingha Prescod (2015), Olympic fencer Ramit Tandon (2015), professional squash player Jakub Buczek (2016), Canadian Olympic rower Sasha DiGiulian (2016), world champion climber Jacqueline Dubrovich (2016), Olympic fencer Maodo Lô (2016), German basketball player for Brose Bamberg Robb Paller (2016), American-Israeli Olympic baseball player Jeff Coby (2017), American basketball player for Xuventude Baloncesto Cameron Nizialek (2017), football player for Atlanta Falcons Akua Obeng-Akrofi (2018), Ghanaian sprinter Charlotte Buck (2018), Olympic rower Osama Khalifa (2018), #1 ranked college squash player in the U.S. for the 2016–17 season Camille Zimmerman (2018), American basketball player for Norrköping Dolphins Yasmeen Al-Dabbagh (2019), Saudi Arabian sprinter Jessica Antiles (2019), swimmer who won silver and bronze medals in the 2017 Maccabiah Games Dylan Castanheira (2019), soccer player, goalkeeper for Fort Lauderdale CF Sophie Whitehouse (2019), goalkeeper for Republic of Ireland women's national football team Mike Smith (2020), basketball player Anthony Jackie Tang (2020), Hong Kong tennis player John Tanguay (2020), rower who won a silver medal in the 2020 Summer Paralympics Dylan Geick* (2021), wrestler and internet personality Velavan Senthilkumar (2021), British Junior Open Squash champion and Asian Junior Squash champion Nastasya Generalova (2023), gymnast and model Olivia Giaccio (2024), Olympic freestyle skier Evita Griskenas (2024), rhythmic gymnast Camden Pulkinen (2024), figure skater Abbey Hsu (2024), basketball player
Special state certification in the United States is required only in four states: California, Washington, Nevada, and Louisiana. A phlebotomist can become nationally certified through many different organizations. However, California currently only accepts national certificates from six agencies. These include the American Certification Agency (ACA), American Medical Technologists (AMT), American Society for Clinical Pathology (ASCP), National Center for Competency Testing/Multi-skilled Medical Certification Institute (NCCT/MMCI), National Credentialing Agency (NCA), and National Healthcareer Association (NHA). These and other agencies such as the American Society of Phlebotomy Technicians also certify phlebotomists outside the state of California. To qualify to sit for an examination, candidates must complete a full phlebotomy course and provide documentation of clinical or laboratory experience.
Each tRNA has an exposed sequence of three nucleotides, known as the anticodon, which are complementary in sequence to a specific codon that may be present in mRNA. For example, the first codon encountered is the start codon composed of the nucleotides AUG. The correct tRNA with the anticodon (complementary 3 nucleotide sequence UAC) binds to the mRNA using the ribosome. This tRNA delivers the correct amino acid corresponding to the mRNA codon, in the case of the start codon, this is the amino acid methionine. The next codon (adjacent to the start codon) is then bound by the correct tRNA with complementary anticodon, delivering the next amino acid to ribosome. The ribosome then uses its peptidyl transferase enzymatic activity to catalyze the formation of the covalent peptide bond between the two adjacent amino acids. The ribosome then moves along the mRNA molecule to the third codon. The ribosome then releases the first tRNA molecule, as only two tRNA molecules can be brought together by a single ribosome at one time. The next complementary tRNA with the correct anticodon complementary to the third codon is selected, delivering the next amino acid to the ribosome which is covalently joined to the growing polypeptide chain. This process continues with the ribosome moving along the mRNA molecule adding up to 15 amino acids per second to the polypeptide chain. Behind the first ribosome, up to 50 additional ribosomes can bind to the mRNA molecule forming a polysome, this enables simultaneous synthesis of multiple identical polypeptide chains.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.